Patents by Inventor Gerd R. Burmester

Gerd R. Burmester has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Predictive mRNA Biomarkers for the Prediction of the Treatment with Methotrexate (MTX)
    Publication number: 20170058348
    Abstract: The present invention concerns predictive mRNA biomarkers, which are used in combination with HLA-DRB4 for forecasting the treatment with MTX (methotrexate). The present invention further concerns a method for forecasting the treatment with MTX (methotrexate), comprising detection of the predictive mRNA biomarkers in combination with HLA-DRB4 in patient samples, whereby the patients are classified into responders or non-responders.
    Type: Application
    Filed: February 13, 2015
    Publication date: March 2, 2017
    Inventors: Bruno STUHLMÜLLER, Karsten MANS, Thomas HÄUPL, Gerd-R. BURMESTER
  • Methods for determining efficacy of TNF-? inhibitors for treatment of rheumatoid arthritis
    Patent number: 9399061
    Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: July 26, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Hartmut Kupper, Jeffrey D. Kent, Mary A. Cifaldi, John L. Perez, Gerd R. Burmester, Philip Mease, Daniel J. Lovell, Edward Keystone, Arthur Kavanaugh
  • Uses and compositions for treatment of rheumatoid arthritis
    Publication number: 20080166348
    Abstract: The invention provides methods, uses and compositions for the treatment of rheumatoid arthritis. The invention describes methods and uses for treating rheumatoid arthritis wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment of rheumatoid arthritis in a subject.
    Type: Application
    Filed: April 10, 2007
    Publication date: July 10, 2008
    Inventors: Hartmut Kupper, Jeffrey D. Kent, Mary A. Cifaldi, John L. Perez, Gerd R. Burmester, Philip Mease, Daniel J. Lovell, Edward Keystone, Arthur Kavanaugh
  • Artificial tissues, methods for the production and the use thereof
    Patent number: 6143501
    Abstract: The invention relates to new artificial tissues which comprise three-dimensional extracellular matrixes (ECM) in cross-linkable structures, cell interaction systems for inducing artificial three-dimensional tissues and which comprise genetically manipulated cells releasing immunosuppressive or cell-differentiating factors. The tissues according to the invention are suitable for producing vital transplants and for establishing models of diseases.
    Type: Grant
    Filed: March 16, 1999
    Date of Patent: November 7, 2000
    Inventors: Michael Sittinger, Olaf Schultz, Gerd R. Burmester, Thomas E. M. Haupl
  • Artificial tissues, methods for the production and the use thereof
    Patent number: 5932459
    Abstract: The invention relates to new artificial tissues which comprise three-dimensional extracellular matrixes (ECM) in cross-linkable structures, cell interaction systems for inducing artificial three-dimensional tissues and which comprise genetically manipulated cells releasing immunosuppressive or cell-differentiating factors. The tissues according to the invention are suitable for producing vital transplants and for establishing models of diseases.
    Type: Grant
    Filed: August 15, 1997
    Date of Patent: August 3, 1999
    Inventors: Michael Sittinger, Olaf Schultz, Gerd R. Burmester, Thomas E. M. Haupl